{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"265"},{"groupId":"OG001","value":"265"}],"units":"Participants"}],"title":"Pre-treatment deaths"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"37"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"265"},{"groupId":"OG001","value":"265"}],"units":"Participants"}],"title":"On-treatment deaths"},{"categories":[{"measurements":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"122"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"247"},{"groupId":"OG001","value":"228"}],"units":"Participants"}],"title":"Post-treatment deaths"},{"categories":[{"measurements":[{"groupId":"OG000","value":"161"},{"groupId":"OG001","value":"160"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"265"},{"groupId":"OG001","value":"265"}],"units":"Participants"}],"title":"All deaths"}],"denoms":[{"counts":[{"groupId":"OG000","value":"265"},{"groupId":"OG001","value":"265"}],"units":"Participants"}],"description":"Deaths were collected from randomization until the end of the trial, approx. 52 months, including post-treatment survival follow up period.","groups":[{"description":"Participants were randomized to sabatolimab plus Azacitidine","id":"OG000","title":"Sabatolimab (MBG453) + Azacitidine"},{"description":"Participants were randomized to placebo plus Azacitidine","id":"OG001","title":"Placebo + Azacitidine"}],"paramType":"NUMBER","populationDescription":"Clinical database population: All randomized participants: participants who died before treatment, during treatment and post-treatment.","reportingStatus":"POSTED","timeFrame":"from randomization until end of trial, up to approx. 52 months","title":"All Collected Deaths","type":"POST_HOC","unitOfMeasure":"Participants"}